Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris

被引:135
作者
Lin, MS
Swartz, SJ
Lopez, A
Ding, X
FernandezVina, MA
Stastny, P
Fairley, JA
Diaz, LA
机构
[1] MED COLL WISCONSIN, DEPT DERMATOL, MILWAUKEE, WI USA
[2] VET ADM MED CTR, MILWAUKEE, WI 53226 USA
[3] UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA
关键词
pemphigus vulgaris; desmoglein-3; T lymphocytes; MHC II restriction; cytokines;
D O I
10.1172/JCI119130
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pemphigus vulgaris (PV) is a cutaneous autoimmune disease characterized by blister formation in the suprabasilar layers of skin and mucosae and anti-desmoglein-3 (Dsg3) autoantibodies bound to the surface of lesional keratinocytes and circulating in the serum of patients. This disease can be reproduced in neonatal mice by passive transfer of patients' IgG, indicating that humoral immunity plays an important role in the pathogenesis of PV. Currently, the role of T lymphocytes in the development of PV is not clear. Here, we report that three immunoreactive segments of the ectodomain of Dsg3 specifically induced proliferation of T cells from PV patients. We found that T lymphocytes from 13 out of 14 patients responded to at least one of three Dsg3 peptides. T cells from controls and other patient groups did not respond to these Dsg3 peptides. The major T cell population stimulated by these Dsg3 peptides was CD4 positive. Dsg3-specific T cell lines and clones were developed and were shown to express a CD4 positive memory T cell phenotype. Upon stimulation, these cell lines and clones secreted a Th2-like cytokine profile. The Dsg3 responses of these T cells were restricted to HLA-DR, and not -DQ and -DP, of the major histocompatibility complex. This information will help to elucidate the cellular immune abnormalities leading to production of pathogenic IgG autoantibodies in patients with PV.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 53 条
[1]   PRODUCTION OF HYBRIDOMA GROWTH-FACTOR BY HUMAN-MONOCYTES [J].
AARDEN, LA ;
DEGROOT, ER ;
SCHAAP, OL ;
LANSDORP, PM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (10) :1411-1416
[2]   MAJOR HISTOCOMPATIBILITY COMPLEX HAPLOTYPE STUDIES IN ASHKENAZI JEWISH PATIENTS WITH PEMPHIGUS-VULGARIS [J].
AHMED, AR ;
YUNIS, EJ ;
KHATRI, K ;
WAGNER, R ;
NOTANI, G ;
AWDEH, Z ;
ALPER, CA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (19) :7658-7662
[3]   MAJOR HISTOCOMPATIBILITY COMPLEX HAPLOTYPES AND CLASS-II GENES IN NON-JEWISH PATIENTS WITH PEMPHIGUS VULGARIS [J].
AHMED, AR ;
WAGNER, R ;
KHATRI, K ;
NOTANI, G ;
AWDEH, Z ;
ALPER, CA ;
YUNIS, EJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :5056-5060
[4]   T-CELLS RESPONSIVE TO MYELIN BASIC-PROTEIN IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
ALLEGRETTA, M ;
NICKLAS, JA ;
SRIRAM, S ;
ALBERTINI, RJ .
SCIENCE, 1990, 247 (4943) :718-721
[5]   AUTOANTIBODIES AGAINST A NOVEL EPITHELIAL CADHERIN IN PEMPHIGUS-VULGARIS, A DISEASE OF CELL-ADHESION [J].
AMAGAI, M ;
KLAUSKOVTUN, V ;
STANLEY, JR .
CELL, 1991, 67 (05) :869-877
[6]   EXTRACELLULAR DOMAIN OF PEMPHIGUS-VULGARIS ANTIGEN (DESMOGLEIN-3) MEDIATES WEAK HEMOPHILIC ADHESION [J].
AMAGAI, M ;
KARPATI, S ;
KLAUSKOVTUN, V ;
UDEY, MC ;
STANLEY, JR .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) :402-408
[7]   AUTOANTIBODIES AGAINST THE AMINO-TERMINAL CADHERIN-LIKE BINDING DOMAIN OF PEMPHIGUS-VULGARIS ANTIGEN ARE PATHOGENIC [J].
AMAGAI, M ;
KARPATI, S ;
PRUSSICK, R ;
KLAUSKOVTUN, V ;
STANLEY, JR .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :919-926
[8]   ABSORPTION OF PATHOGENIC AUTOANTIBODIES BY THE EXTRACELLULAR DOMAIN OF PEMPHIGUS-VULGARIS ANTIGEN (DSG3) PRODUCED BY BACULOVIRUS [J].
AMAGAI, M ;
HASHIMOTO, T ;
SHIMIZU, N ;
NISHIKAWA, T .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :59-67
[9]   INDUCTION OF PEMPHIGUS IN NEONATAL MICE BY PASSIVE TRANSFER OF IGG FROM PATIENTS WITH THE DISEASE [J].
ANHALT, GJ ;
LABIB, RS ;
VOORHEES, JJ ;
BEALS, TF ;
DIAZ, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (20) :1189-1196
[10]  
ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671